Увійти

Готові списки джерел за темами / Antibodies / Статті в журналах

Статті в журналах з теми "Antibodies"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Antibodies.

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 25 травня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Antibodies".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Deora, Kanika, and Ruchee Khanna. "Clinical Profile of the Patients with Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibodies." Indian Journal of Forensic Medicine and Pathology 12, no. 3 (2019): 195–99. http://dx.doi.org/10.21088/ijfmp.0974.3383.12319.6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Chiswell, David J., and John McCaffery. "Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?" Trends in Biotechnology 10 (1992): 80–84. http://dx.doi.org/10.1016/0167-7799(92)90178-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Linhardt, Robert J., C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield, et al. "Monoclonal antibodies and immobilized antibodies." Applied Biochemistry and Biotechnology 15, no. 1 (June 1987): 53–80. http://dx.doi.org/10.1007/bf02798506.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Favoreel, Herman W., Geert Van Minnebruggen, Gerlinde R. Van de Walle, Jolanta Ficinska, and Hans J. Nauwynck. "Herpesvirus interference with virus-specific antibodies: Bridging antibodies, internalizing antibodies, and hiding from antibodies." Veterinary Microbiology 113, no. 3-4 (March 2006): 257–63. http://dx.doi.org/10.1016/j.vetmic.2005.11.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Clark, A. "Antibodies." Journal of Clinical Pathology 42, no. 5 (May 1, 1989): 559. http://dx.doi.org/10.1136/jcp.42.5.559-c.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Bradbury, Andrew, Nileena Velappan, Vittorio Verzillo, Milan Ovecka, Leslie Chasteen, Daniele Sblattero, Roberto Marzari, Jianlong Lou, Robert Siegel, and Peter Pavlik. "Antibodies in proteomics I: generating antibodies." Trends in Biotechnology 21, no. 6 (June 2003): 275–81. http://dx.doi.org/10.1016/s0167-7799(03)00112-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Kounis, Nicholas G., George D. Soufras, and George N. Kounis. "Antibodies against antibodies inducing Kounis syndrome." International Journal of Cardiology 168, no. 5 (October 2013): 4804–5. http://dx.doi.org/10.1016/j.ijcard.2013.07.037.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Trier, Nicole, Paul Hansen, and Gunnar Houen. "Peptides, Antibodies, Peptide Antibodies and More." International Journal of Molecular Sciences 20, no. 24 (December 13, 2019): 6289. http://dx.doi.org/10.3390/ijms20246289.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.

9

Shoenfeld, Yehuda. "The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies." Nature Medicine 10, no. 1 (January 2004): 17–18. http://dx.doi.org/10.1038/nm0104-17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Bobrovnik, S. A., M. O. Demchenko, and S. V. Komisarenko. "Effect of trifluoroethanol on antibodies binding properties." Ukrainian Biochemical Journal 95, no. 1 (April 26, 2023): 20–30. http://dx.doi.org/10.15407/ubj95.01.020.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The studies on the influence of organic co-solvents on the structure and function of antibodies are of key interest, especially in view of antibodies broad use as recognizing elements in different analytical systems. Here we studied the effect of co-solvent 2,2,2-trifluoroethanol (TFE) on the ability of anti-ovalbumin monoclonal antibodies to interact with its specific antigen. Antibody affinity to antigen and the rate constants of antibody binding to immobilized antigen were analyzed. Changes in antibody reactivity with incubation time which depended on TFE concentration and temperature were revealed. When treatment of antibodies with TFE was carried out at 0°C, we observed nonlinear, non-monotonous changes of antibody reactivity with initial fast decrease and substantial increase that may be related to the loss of antigen binding reactivity by some part of antibodies at the start but its restoration when the incubation proceeds. Keywords: 2;2;2-trifluoroethanol, antibody affinity, antigen-antibody interaction, monoclonal antibodies, ovalbumin

11

Dahl, Mark V., and Alina G. Bridges. "Intravenous immune globulin: Fighting antibodies with antibodies." Journal of the American Academy of Dermatology 45, no. 5 (November 2001): 775–83. http://dx.doi.org/10.1067/mjd.2001.119085.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

SHITARA, Kenya. "Potelligent Antibodies as Next Generation Therapeutic Antibodies." YAKUGAKU ZASSHI 129, no. 1 (January 1, 2009): 3–9. http://dx.doi.org/10.1248/yakushi.129.3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Methe, H. "Antibodies Stop Secretion of Antibodies in Lupus." Science Translational Medicine 4, no. 141 (July 4, 2012): 141ec115. http://dx.doi.org/10.1126/scitranslmed.3004529.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Filatova, Elena A., Grigory B. Krapivinsky, Grigory N. Filatov, Alisa V. Lazareva, and Evgeny E. Fesenko. "Antiidiotypic antibodies against anti-cGMP polyclonal antibodies." Biochimica et Biophysica Acta (BBA) - Biomembranes 1064, no. 2 (May 1991): 293–96. http://dx.doi.org/10.1016/0005-2736(91)90314-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Qian, J., Y. Xing, D. Yufang, X. Deng, J. Zhao, Q. Wang, Z. Tian, M. LI, and X. Zeng. "OP0216 THE CLINICAL AND PATHOLOGICAL ROLES OF AUTOANTIBODIES TARGETING BMP SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 141.1–142. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3682.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

BackgroundPulmonary arterial hypertension (PAH) is one of the most severe complications and the leading cause of death in patients with systemic lupus erythematosus (SLE). Pathogenic mechanisms leading to SLE-PAH are still not fully understood. In idiopathic PAH, the dysfunction of the bone morphogenetic protein (BMP) pathway was found to be involved in pulmonary artery remodeling [1]. In SLE-PAH, our previous study identified serum autoantibodies targeting BMP receptors (BMPR) as the potential biomarker, including anti-BMPR2, BMPR1A, and Activin Receptor-Like Kinase type 1 (ALK1) antibodies [2]. However, the clinical and pathological roles of the above autoantibodies targeting BMP signaling in SLE-PAH remain uncertain.ObjectivesTo investigate the clinical and pathological roles of autoantibodies targeting BMPR2, BMPR1A, and ALK1 in SLE-PAH.MethodsPatients of SLE-PAH confirmed by right heart catheterization were enrolled and serum levels of autoantibodies targeting BMPR2, BMPR1A, and ALK1 were measured by ELISA. Patients with SLE-PAH were subtyped by cluster analysis. Survival and treatment goal achievement were further compared between different clusters. The Id1 and phospho-SMAD1/5 (p-SMAD1/5) levels were examined in human pulmonary artery endothelial cells (hPAEC) under the induction of BMP9 combined with anti-BMPR2, anti-ALK1, and anti-BMPR1A neutralizing antibodies (5 μg/mL). The effect of anti-ALK1 antibodies on the extent of monolayer permeability and apoptosis of hPAEC was further examined.Results60 SLE-PAH patients were enrolled and cluster analysis revealed two distinct clusters according to the positivity of autoantibodies targeting BMP signaling and clinical manifestations. Cluster 1 was a “low-antibody and high-disease activity” cluster while cluster 2 was a “high-antibody and low-disease activity” cluster. Patients in cluster 1 showed a higher proportion of nephropathy (76.9%) and SLE activity, however a low positivity rate of autoantibodies targeting BMP signaling. Patients in cluster 2 were characterized by a higher rate of anti-BMPR2 antibodies (82.4%), anti-ALK antibodies (70.6%), and lower SLE activity. Prognostic analysis showed that the proportion of patients who reached the treatment target was relatively higher in cluster 2. Mechanism study showed that the p-SMAD1/5 level and the Id1expression were decreased, indicating the suppression of BMP signaling in the presence of anti-ALK1 antibodies. Functional studies showed that anti-ALK1 antibodies increased the monolayer permeability of hPAEC. The late-stage apoptosis of hPAECs was also induced by anti-ALK1 antibodies.Table 1.The clinical features of the patients in cluster 1 and cluster 2.Cluster 1 (N=26)Cluster 2 (N=34)PAnti-BMPR2 antibodies5(19.2)28(82.4)<0.001Anti-BMPR1A antibodies8(30.2)4(1.8)0.068Anti-ALK antibodies5(19.2)24(70.6)<0.001Arthritis12(46.2)25(73.5)0.031Nephropathy20(76.9)1(2.9)<0.001SLEDAI5.46±4.282.62±2.100.001WHO III/IV17(65.4)14(41.2)0.063Figure 1.(A). Kaplan-Meier analysis of the prognosis of cluster1 and cluster2. (B) The level of Id1 expression under the induction of anti-BMPR2, anti-ALK1, and anti-BMPR1A antibodies in the presence or absence of BMP9. The ID1 (C) and p-Smad 1/5/8 (D) measured by western blotting under the induction of anti-ALK antibodies, BMP9, or anti-ALK antibodies+ BMP9. The fluorescence of the receiver plate well solution (E) and the percentage of late-stage apoptotic cells (E) under the induction of anti-ALK neutralizing antibodies.ConclusionThe serum positivity of autoantibodies targeting BMP signaling has clinical potential in dividing SLE-PAH patients into two distinct clusters. The anti-ALK1 antibodies can downregulate BMP signaling and mediate great permeability and apoptosis in hPAECs, which may be involved in the pathogenesis of SLE-PAH.References[1]Dewachter L, et.al. Eur Respir J 34 (5):1100-1110.[2]Xing Y, et.al. FASEB J 35 (12):e22044.AcknowledgementsWe thank CSTAR co-authors as following for assistance with cases collections.Disclosure of InterestsNone Declared.

16

Kapustianenko, L. G. "POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN KRINGLE 5." Biotechnologia Acta 10, no. 3 (June 2017): 41–49. http://dx.doi.org/10.15407/biotech10.03.041.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Khan, Ramsha, Melissa Menard, Chao-Ching Jen, Xi Chen, Peter A. A. Norris, and Alan H. Lazarus. "Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP." Blood 135, no. 26 (June 25, 2020): 2420–24. http://dx.doi.org/10.1182/blood.2019003646.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP). Monoclonal antibodies are desirable alternatives, but none have yet proven successful despite their ability to opsonize erythrocytes (or red blood cells, RBCs) and cause anemia. Here, we examined 12 murine erythrocyte–specific antibodies of different specificity and subtypes and found that 8 of these antibodies could induce anemia in antigen-positive mice. Of these 8 antibodies, only 5 ameliorated ITP. All antibodies were examined for their in vitro ability to support macrophage-mediated phagocytosis of erythrocytes. Antibodies which supported erythrocyte phagocytosis in vitro successfully ameliorated ITP in vivo. To examine the ability of each antibody to inhibit phagocytosis of platelets, the antibodies were used to sensitize erythrocytes in vitro and these were added to a platelet phagocytosis assay. Antibodies that inhibited platelet phagocytosis in vitro also all ameliorated ITP in vivo. We conclude that inducing anemia is not a sufficient condition for amelioration of ITP but that the antibody’s ability to prevent platelet phagocytosis in vitro predicted its ability to ameliorate ITP. We suggest that inhibition of in vitro platelet phagocytosis may prove to be a valuable tool for determining which erythrocyte antibodies would likely be candidates for clinical use in ITP.

18

Heng, Boon Chin, Wenjin Huang, Xiufang Zhong, Ping Yin, and Guo Qing Tong. "Roles of Antiphospholipid Antibodies, Antithyroid Antibodies and Antisperm Antibodies in Female Reproductive Health." Integrative Medicine International 2, no. 1-2 (July 16, 2015): 21–31. http://dx.doi.org/10.1159/000381900.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

BYGREN, P., N. RASMUSSEN, B. ISAKSSON, and J. WIESLANDER. "Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis." European Journal of Clinical Investigation 22, no. 12 (December 1992): 783–92. http://dx.doi.org/10.1111/j.1365-2362.1992.tb01447.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Reddy, Raghuram, Joel Mintz, Roei Golan, Fakiha Firdaus, Roxana Ponce, Derek Van Booven, Aysswarya Manoharan, Isabelle Issa, Bonnie B. Blomberg, and Himanshu Arora. "Antibody Diversity in Cancer: Translational Implications and Beyond." Vaccines 10, no. 8 (July 22, 2022): 1165. http://dx.doi.org/10.3390/vaccines10081165.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression.

21

Yatsenko, T. A. "POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN: PURIFICATION, CHARACTERIZATION AND APPLICATION." Biotechnologia Acta 13, no. 6 (December 2020): 50–57. http://dx.doi.org/10.15407/biotech13.06.050.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The plasminogen/plasmin system plays a crucial role in fibrinolysis and regulation of cell functions in a wide range of normal and pathological processes. Investigation of plasminogen/plasmin functions requires the availability of well-characterized and effective molecular tools, such as antibodies. In the present work, the isolation and characterization of rabbit polyclonal antibodies against human plasminogen are described and approaches for the identification of plasminogen and its fragments using the purified antibodies are demonstrated. For the antibodies isolation, standard animal immunization and blood collection procedures, serum isolation, protein salting out and affinity chromatography were performed. For the antibodies characterization and application, the following methods were used: enzyme linked immunoassay (ELISA), Western blotting, FITC-protein conjugation, flow cytometry and spectrofluorometry. The obtained polyclonal rabbit anti-human plasminogen antibodies interacted with human Glu- and Lys-plasminogen, kringles 1-3 and 1-4 of plasminogen, mini-plasminogen, the heavy and light chain of plasmin. We propose the application of anti-plasminogen antibodies for the direct ELISA, Western blot analysis, and for flow cytometry and spectrofluorometric analysis of plasminogen binding with cells. The obtained anti-plasminogen antibodies are promising tools for the investigation of plasminogen/plasmin system functions, either fibrinolytic or signaling.

22

Triplett, Douglas A. "Antiphospholipid Antibodies." Archives of Pathology & Laboratory Medicine 126, no. 11 (November 1, 2002): 1424–29. http://dx.doi.org/10.5858/2002-126-1424-aa.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Objective.—To review the role of lupus anticoagulants in the pathogenesis of both venous and arterial thromboembolic events, as well as in recurrent spontaneous abortions. The pathophysiology of lupus anticoagulants and associated antiphospholipid antibodies (eg, anticardiolipin antibodies) is also discussed. Data Sources.—Review of the recent medical literature. Data Extraction and Synthesis.—Key articles in the recent medical literature dealing with lupus anticoagulants and their role in pathogenesis of thromboembolic events were reviewed. Plasma proteins that have an affinity for binding to “perturbed cellular membranes” have been identified as the antigenic targets for antiphospholipid antibodies. Thus, the concept of antiphospholipid antibodies needs to be reevaluated. Perhaps a better term is antiprotein-phospholipid antibodies. The principal antigenic protein targets are β2-glycoprotein I, prothrombin, and a wide range of additional proteins that interact with activated cellular membranes, including protein C, protein S, annexin V, etc. Most research reported in the literature has focused on β2-glycoprotein I and human prothrombin.

23

Brinkmann, Ulrich, and Roland E. Kontermann. "Bispecific antibodies." Science 372, no. 6545 (May 27, 2021): 916–17. http://dx.doi.org/10.1126/science.abg1209.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Rieger, Paula Trahan. "Monoclonal Antibodies." American Journal of Nursing 87, no. 4 (April 1987): 469. http://dx.doi.org/10.2307/3470440.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Groner, Bernd, Cord Hartmann, and Winfried Wels. "Therapeutic Antibodies." Current Molecular Medicine 4, no. 5 (August 1, 2004): 539–47. http://dx.doi.org/10.2174/1566524043360483.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Kosmas, C., H. Kalofonos, and A. A. Epenetos. "Monoclonal Antibodies." Drugs 38, no. 5 (November 1989): 645–57. http://dx.doi.org/10.2165/00003495-198938050-00001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Larrick, James W., and Kirk E. Fry. "Recombinant antibodies." Human Antibodies 2, no. 4 (December 1, 1991): 172–89. http://dx.doi.org/10.3233/hab-1991-2401.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Bronson, Richard A. "Sperm Antibodies." Immunology and Allergy Clinics of North America 10, no. 1 (February 1990): 165–84. http://dx.doi.org/10.1016/s0889-8561(22)00256-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Pisetsky, David S. "ANTINUCLEAR ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 2 (May 1994): 371–85. http://dx.doi.org/10.1016/s0889-8561(22)00780-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Smith, J. Bruce, and F. Susan Cowchock. "ANTIPHOSPHOLIPID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (November 1994): 821–34. http://dx.doi.org/10.1016/s0889-8561(22)00345-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Pratt, Donna E. "THYROID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (November 1994): 835–38. http://dx.doi.org/10.1016/s0889-8561(22)00346-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Visan, Ioana. "Enhancing antibodies." Nature Immunology 22, no. 7 (June 28, 2021): 800. http://dx.doi.org/10.1038/s41590-021-00973-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Khamashta, Munther A., and Graham R. V. Hughes. "Antiphospholipid antibodies." Clinical Reviews in Allergy 12, no. 3 (September 1994): 287–96. http://dx.doi.org/10.1007/bf02802323.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Adair, J., and A. Lawson. "Therapeutic Antibodies." Drug Design Reviews - Online 2, no. 3 (May 1, 2005): 209–17. http://dx.doi.org/10.2174/1567269053828800.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Pullen, Richard L. "Antinuclear antibodies." Nursing Made Incredibly Easy! 20, no. 6 (November 2022): 47–48. http://dx.doi.org/10.1097/01.nme.0000884112.83689.31.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Santos-Argumedo, Leopoldo. "Natural Antibodies." Advances in Neuroimmune Biology 3, no. 3,4 (2012): 345–52. http://dx.doi.org/10.3233/nib-012912.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

&NA;. "Monoclonal antibodies." Reactions Weekly &NA;, no. 1293 (March 2010): 36. http://dx.doi.org/10.2165/00128415-201012930-00100.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Hudson, Peter J., and Christelle Souriau. "Engineered antibodies." Nature Medicine 9, no. 1 (January 2003): 129–34. http://dx.doi.org/10.1038/nm0103-129.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Benkovic, Stephen J. "Catalytic Antibodies." Annual Review of Biochemistry 61, no. 1 (June 1992): 29–54. http://dx.doi.org/10.1146/annurev.bi.61.070192.000333.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (July 7, 2008): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1988.00491.x-i1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (January 1990): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1990.tb02530.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Drlicek, M., U. Liszka, W. Grisold, A. Mohn-Staudner, F. Lintner, and K. Jellinger. "Antineuronal antibodies." Neurology 40, no. 11 (November 1, 1990): 1804. http://dx.doi.org/10.1212/wnl.40.11.1804-b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Helmerhorst, F. M., M. J. J. Finken, and J. J. Erwich. "Antisperm antibodies." Human Reproduction 14, no. 7 (July 1999): 1669–71. http://dx.doi.org/10.1093/humrep/14.7.1669.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Worland, PhD, Peter J., Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD, and Jeffrey S. Ross, MD. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 1, 2003): 472–85. http://dx.doi.org/10.1309/y6lp-c0lr-726l-9dx9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Ross, Jeffrey S., Karen Gray, Gary S. Gray, Peter J. Worland, and Mark Rolfe. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 2003): 472–85. http://dx.doi.org/10.1309/y6lpc0lr726l9dx9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Barahona-Garrido, J., J. Camcho-Escobedo, C. Garcia-Martiʼnez, H. Tocay, J. Cabiedes, and J. Yamamoto-Furusho. "Antinuclear antibodies." Inflammatory Bowel Diseases 14 (December 2008): S12. http://dx.doi.org/10.1097/00054725-200812001-00038.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Persidis, Aris. "Catalytic antibodies." Nature Biotechnology 15, no. 12 (November 1997): 1313–15. http://dx.doi.org/10.1038/nbt1197-1313.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Tramontano, A., K. Janda, and R. Lerner. "Catalytic antibodies." Science 234, no. 4783 (December 19, 1986): 1566–70. http://dx.doi.org/10.1126/science.3787261.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

&NA;. "Monoclonal Antibodies." Journal of Pediatric Hematology/Oncology 25, no. 4 (April 2003): S5—S6. http://dx.doi.org/10.1097/00043426-200304000-00025.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

&NA;. "Monoclonal Antibodies." Journal of Pediatric Hematology/Oncology 25, no. 4 (April 2003): S17—S18. http://dx.doi.org/10.1097/00043426-200304000-00036.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.